To determine whether ER signaling activity is a prognostic marker or a biomarker for endocrine therapy response, we first classified samples of breast, ovarian, endometrial, and cervical cancers in the TCGA data sets as having low or high ER signaling activity by determining the EERESs for each sample as described in the “Methods” section. The gene discussed is ESR1; the disease is cervical cancer.